Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
astrazeneca.com

See what CB Insights has to offer

Investments

24

Portfolio Exits

14

Funds

1

Partners & Customers

10

Service Providers

1

About AstraZeneca

AstraZeneca is a biopharmaceutical company that focuses on the discovery, development, manufacturing, distribution and worldwide commercialization of primary care and specialty care medicines.

AstraZeneca Headquarter Location

1 Francis Crick Avenue Cambridge Biomedical Campus

Cambridge, England, CB2 0AA,

United Kingdom

+44 (0)20 3749 5000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AstraZeneca

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find AstraZeneca in 6 Expert Collections, including Digital Therapeutics.

D

Digital Therapeutics

345 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

S

Synthetic Biology

382 items

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Industrial SynBio

382 items

Synthetic biology focused on replacing industrial and commercial materials.

N

Nanobiotechnology

707 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

AstraZeneca Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AstraZeneca Rank

Latest AstraZeneca News

AstraZeneca $360m investment is a major boost for Ireland

Sep 23, 2021

John Kennedy Share Share AstraZeneca ’s decision to invest $360m in an advanced manufacturing facility in Ireland will transform the development and commercialisation of new medicines. This week another jewel was added to Ireland’s pharma crown when it emerged that AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure the Company’s global supply network is fit for future growth. The new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility. “This very significant will create highly skilled jobs, nurture the country’s dynamic life sciences sector and allow for the development of high value-added medicines” The $360m planned investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs. The project, which will provide an important boost to the local economy and to the country’s life-sciences sector, was developed with the support and collaboration of Ireland’s investment agency, IDA Ireland. Next-generation pharma “This $360 million investment represents a significant commitment to Ireland and will see 100 jobs being created,” Taoiseach Micheál Martin, TD, said. “In choosing Ireland as the location for its new next-generation active pharmaceutical ingredient manufacturing facility, AstraZeneca joins the very strong and successful network of global life sciences companies we have in Ireland. I wish them every success with their operations here.” The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes, contributing to the Company’s Ambition Zero Carbon programme. The industry-leading, future proof design of the plant will permit the addition of capability to manufacture a wide range of medicines, including new modalities such as antibody drug conjugates and oligonucleotides. “This is a tremendously proud moment for us all at AstraZeneca and I am delighted that we are bringing this very significant investment to Dublin which, with the support of the IDA, will create highly skilled jobs, nurture the country’s dynamic life sciences sector and allow for the development of high value-added medicines,” said Pascal Soriot, CEO of AstraZeneca. The industry-leading, future proof design of the plant will permit the addition of capability to manufacture a wide range of medicines, including new modalities such as antibody drug conjugates and oligonucleotides. “The future manufacturing of APIs for our medicines includes compounds with highly complex synthesis, requiring next generation technologies and capabilities that can respond quickly and nimbly to rapidly-changing clinical and commercial needs,” explained Pam Cheng, executive vice-president of Global Operations and IT at AstraZeneca. “This significant investment will ensure the AstraZeneca supply network is fit for the future.” Main image at top: The existing College Park site where the new campus will be built

AstraZeneca Investments

24 Investments

AstraZeneca has made 24 investments. Their latest investment was in VaxEquity as part of their Corporate Minority on September 9, 2021.

CBI Logo

AstraZeneca Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/23/2021

Corporate Minority

VaxEquity

Yes

3

9/16/2020

Series A

OnDosis

$3.4M

Yes

3

10/23/2018

Corporate Minority - P2P

Innate Pharma

$6.26M

Yes

1

9/5/2018

Series D

Subscribe to see more

$99M

Subscribe to see more

10

2/8/2018

Series D - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/23/2021

9/16/2020

10/23/2018

9/5/2018

2/8/2018

Round

Corporate Minority

Series A

Corporate Minority - P2P

Series D

Series D - II

Company

VaxEquity

OnDosis

Innate Pharma

Subscribe to see more

Subscribe to see more

Amount

$3.4M

$6.26M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

3

1

10

10

AstraZeneca Portfolio Exits

14 Portfolio Exits

AstraZeneca has 14 portfolio exits. Their latest portfolio exit was Rani Therapeutics on July 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/30/2021

IPO

$991

3

11/2/2020

Divestiture

$991

1

10/28/2020

IPO

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

7/30/2021

11/2/2020

10/28/2020

00/00/0000

00/00/0000

Exit

IPO

Divestiture

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

1

2

10

10

AstraZeneca Acquisitions

16 Acquisitions

AstraZeneca acquired 16 companies. Their latest acquisition was Alexion Pharmaceuticals on July 21, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/21/2021

IPO

$991

$26.2M

Acq - P2P

28

12/17/2015

Series B

$991

$13M

Corporate Majority

4

11/6/2015

IPO

$991

$109.5M

Acq - P2P

9

1/1/2015

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/4/2014

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/21/2021

12/17/2015

11/6/2015

1/1/2015

11/4/2014

Investment Stage

IPO

Series B

IPO

Series B

Series C

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$26.2M

$13M

$109.5M

$99M

$99M

Note

Acq - P2P

Corporate Majority

Acq - P2P

Subscribe to see more

Subscribe to see more

Sources

28

4

9

10

10

AstraZeneca Fund History

1 Fund History

AstraZeneca has 1 fund, including AstraZeneca Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/14/2020

AstraZeneca Fund

$229M

1

Closing Date

2/14/2020

Fund

AstraZeneca Fund

Fund Type

Status

Amount

$229M

Sources

1

AstraZeneca Partners & Customers

10 Partners and customers

AstraZeneca has 10 strategic partners and customers. AstraZeneca recently partnered with Aridis Pharmaceuticals on August 8, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

8/12/2021

Licensee

Aridis Pharmaceuticals

United States

09:00 ET Aridis Pharmaceuticals Announces Second Quarter 2021 Results

AR-320 : The Company announced the licensing of this Phase 3-ready asset from AstraZeneca in July 2021 .

1

8/9/2021

Partner

Daiichi Sankyo

Japan

1

7/27/2021

Partner

Regeneron Pharmaceuticals

United States

AstraZeneca teams up with Regeneron for obesity-busting drug pact focused on genetics

`` As experts on genetics and human biology , Regeneron is excited to join forces with the chemistry and small molecule leaders at AstraZeneca , as we seek to develop new medicines tackling the harmful and costly obesity epidemic . ''

2

6/18/2021

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/17/2021

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/12/2021

8/9/2021

7/27/2021

6/18/2021

6/17/2021

Type

Licensee

Partner

Partner

Client

Client

Business Partner

Aridis Pharmaceuticals

Daiichi Sankyo

Regeneron Pharmaceuticals

Country

United States

Japan

United States

Subscribe to see more

Subscribe to see more

News Snippet

09:00 ET Aridis Pharmaceuticals Announces Second Quarter 2021 Results

AR-320 : The Company announced the licensing of this Phase 3-ready asset from AstraZeneca in July 2021 .

AstraZeneca teams up with Regeneron for obesity-busting drug pact focused on genetics

`` As experts on genetics and human biology , Regeneron is excited to join forces with the chemistry and small molecule leaders at AstraZeneca , as we seek to develop new medicines tackling the harmful and costly obesity epidemic . ''

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

AstraZeneca Service Providers

1 Service Provider

AstraZeneca has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

AstraZeneca Team

56 Team Members

AstraZeneca has 56 team members, including current Chief Executive Officer, Pascal Soriot.

Name

Work History

Title

Status

Pascal Soriot

Chief Executive Officer

Current

Bahija Jallal Ph.D.

Chiron, Sugen, and MedImmune

President, Executive Vice President

Current

Bahija Jallal

Executive Vice President

Current

Menelas Pangalos

Executive Vice President

Current

Susan Galbraith

Senior Vice President

Current

Name

Pascal Soriot

Bahija Jallal Ph.D.

Bahija Jallal

Menelas Pangalos

Susan Galbraith

Work History

Chiron, Sugen, and MedImmune

Title

Chief Executive Officer

President, Executive Vice President

Executive Vice President

Executive Vice President

Senior Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.